Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Montenegro has been experiencing a steady growth in recent years.
Customer preferences: Montenegro's population is aging, leading to an increase in demand for pharmaceutical products. Additionally, the country has a high prevalence of chronic diseases, such as cardiovascular diseases, diabetes, and cancer, which require long-term treatment and medication.
Trends in the market: The pharmaceutical industry in Montenegro is dominated by multinational companies, which account for the majority of the market share. However, there has been a recent trend towards the development of domestic pharmaceutical companies, which are focusing on the production of generic drugs. This is due to the government's efforts to reduce healthcare costs by promoting the use of cheaper generic drugs.
Local special circumstances: Montenegro's healthcare system is undergoing significant reforms, aimed at improving the quality of care and reducing costs. As part of these reforms, the government has introduced a new system for the reimbursement of drugs, which is expected to increase the affordability of pharmaceutical products for patients. Additionally, the government is investing in the development of the country's healthcare infrastructure, which is expected to boost the demand for pharmaceutical products.
Underlying macroeconomic factors: Montenegro's economy is heavily dependent on tourism, which has been negatively impacted by the COVID-19 pandemic. However, the pharmaceutical industry has remained resilient, as demand for healthcare products has increased due to the pandemic. Additionally, the country's accession to the European Union is expected to provide new opportunities for the pharmaceutical industry, as it will allow for easier access to the EU market and increased investment in the sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)